Educational Module

Educational Module 6 - Lifestyle considerations for your HCM patient

Course Overview

This content was accurate at the time of release, 1 November 2021. Accreditation for this course expired on 2 November 2023. If you would still like an activity completion certificate, send your request to [email protected].

This online learning module is designed to raise awareness for HCM and provide you with an understanding of the lifestyle recommendations you might make to your HCM patients to ensure long-term health and quality of life. It assists clinicians in community practice or those with an interest in HCM management to:  

  • recognise the importance and the benefits of moderate exercise  
  • be aware of potential drug-drug interactions with medications typically prescribed to HCM patients, and know which drugs should be avoided 
  • appreciate that certain occupations may pose a risk to HCM patients (and their co-workers or the public) 
  • advise that pregnancy is well tolerated in HCM patients 
  • know when referral to an HCM expert center is appropriate 

This online learning module is designed to be completed in 60 minutes.  

Target audience: Family/general physicians, general/community cardiologists, cardiac nurses, paediatricians, paediatric nurses, genetic counselors 

Funding disclosure: This activity is supported by educational grant funding from Bristol Myers Squibb, Cytokinetics and Sanofi.  

Learners may participate in this educational activity free of charge. 

  • Exercise recommendations 
  • Drugs and supplements 
  • Work restrictions 
  • Pregnancy 
  • Obesity 

By the end of this activity, learners will be able to: 

  • Recount recommendations for physical activity in hypertrophic cardiomyopathy (HCM) patients and formulate appropriate plans for an example patient 
  • Recall medications that are contraindicated for HCM patients and why 
  • Outline applicable occupational restrictions for HCM patients and utilize this on an example case 
  • Summarize considerations for pregnant HCM patients and plan appropriate clinical management for the duration of pregnancy 
  • Explain the impact of obesity on HCM disease progression and risks to the patient and apply this knowledge to an example case 

Accreditation for this course has expired. You may view the program, but CME / CE is no longer available and no certificate will be issued.

Dr John Lynn Jefferies, MD, Professor and Chief of Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease, Methodist University Hospital/ University of Tennessee, St Jude Children’s Research Hospital, has received financial compensation for consulting for Abbott, Novartis, and Pfizer, and received research grants from Myokardia, Abbott, Novartis, and Pfizer. 

Lisa Salberg, Founder and CEO of the Hypertrophic Cardiomyopathy Association (HCMA), has no relevant conflicts of interest to disclose. 

Disclosure of educational planners: 

Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.  

Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose. 

All relevant financial relationships have been mitigated.